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ABSTRACT 
Psoriasis and psoriatic arthritis are a chronic skin disease of autoimmune system that is identified as patches of abnormal s kin, affecting 2-5% 
of the world’s population. Psoriasis is an incurable lifetime disease which can be controlled and relieved through medication. Various 
approaches have been explored to treat the disease. Treatment of psoriasis includes topical therapy, systemic therapy and pho totherapy. 
Topical therapy is the main psoriasis treatment. However, the conventional topical treatment such as gel and cream have low efficiency to  poor 
cosmetic and aesthetic appeal leading to poor patient compliance or adherence. Nanoemulsions are transparent or translucent d ispersions, 
having the droplet size less than 100 nm with ultra-low interfacial tension, large o/w interfacial areas and long term physical stability recently, 
much attention has been paid to the application of Nano emulsion as drug delivery system. A small droplet size would enhance the drug 
delivery and penetration of a drug through the psoriasis skin layer. A good selection of oils and surfactants would enhance the transdermal 
treatment efficacy in psoriatic patient. 
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INTRODUCTION  
Psoriasis is one of the skin diseases, affecting 2–5% of the 
world's population. Psoriasis is a skin autoimmune disorder, 
resulting in an excessive growth and aberrant differentiation 
of keratinocytes. This disease could develop at any age, but it 
usually occurs before the age of 40, and is quite uncommon 
in children. Psoriasis is not life threatening, but it is a 
debilitating chronic illness with pronounced physical, 
psychological and social implications. In addition, 
approximately 5–8% of patients with psoriasis developed 
psoriatic arthritis, which causes much pain and further 
reduced mobility.1 
Psoriasis is a T-cell-mediated autoimmune inflammatory 
skin disease that manifests in such symptoms as skin-surface 
inflammation, epidermal proliferation, hyperkeratosis, 
angiogenesis, and abnormal keratinization.27as for psoriatic 
skin, the mitotic activity of basal keratinocytes is 50-fold 
compared to normal skin activity. Therefore, keratinocytes of 
psoriatic skin have only 3–5 days to be removed from the 
basal layer to the cornified layer (28–30 days for normal 
skin). This limited period, accompanied by rapid 
differentiation activity, causes the dead skin to be 
accumulated on the skin’s surface, resulting in a thick and 
dry skin surface. More simply, psoriasis presents as thick 
patches of red, dry, and itchy skin. Treatments can only help 
to reduce and relieve the problems, not cure them. The 
current standard treatment for managing psoriasis includes 
topical therapy as first-line treatment for mild disease, 
followed by phototherapy and systemic (or oral) therapy for 
more severe disease.28 
In addition, approximately 5–8% of patients with psoriasis 
developed psoriatic arthritis, which causes much pain and 
further reduced mobility.1 They also experience extreme 
itching of the skin, which leads to scaly, painful and 
disgorging lesions. Typical skin lesions affected by psoriasis 
can be observed clearly and the coverage area is well 
defined. When the coverage area of the affected body surface 
is more than 20%, the condition is categorized as a severe 
case.2 The area involved is not limited to any specific part of 
the body as the disease could be found a sminor spots which 
are distributed over the entire skin.3 Visible psoriasis 
conditions with very thick and red patches may give an 
impact on the psychosocial lives of patients, especially to 
their social interactions.4 Overall, patients with psoriasis 
oven describe the feelings of self-consciousness, 
helplessness, embarrassment, anger and frustration,5,6 which 
would eventually lead to low self-esteem, lack of self-
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condensed, poor self-image and generally lower sense of 
well-being.7 Recently, psoriasis was found to be associated 
with many diseases such as independent risk factor for 
diabetes and cardiovascular diseases, including hypertension 
and hypercholesterolemia. 8,9 The relation between psoriasis 
with cardio metabolic disorder such as hypertension, obesity 
and chronic kidney disease was reported10 and has been 
confirmed through investigation in pediatric patients.11 For 
example, a study was found that the obesity in children with 
psoriasis tobe 1.7 times higher in frequency when compared 
with the children without psoriasis.12 
 This disease has different types: psoriasis vulgar is, guttate 
psoriasis, erythrodermic psoriasis, pustular psoriasis and 
nail psoriasis. The first type is the most common form of 
psoriasis, which is characterized by red, scaly and raised 
plaques. Classic psoriasis vulgaris mainly infects specific 
areas such as elbows, knees and the scalp. It can also remain 
localized or become generalized over time and the plaques 
may differ in size 29,30. Treatment of psoriasis depends on 
many factors such as the extent of the disease, its influence 
on patient's life, and the life perception of patient's illness 30.  
 
Table 1: Classification of Psoriasis45 
 
 
Plaque 
psoriasis 
 
Most people have plaque psoriasis. This looks like patches of 
pink or red skin covered with silvery white scales (sometimes 
called plaques). The silvery white scales are dead skin cells. 
The patches are slightly raised from the surface of the skin.  
 
 
 
Pustular 
psoriasis 
 
This can be a severe type of psoriasis where lots of small 
blisters appear on your skin. It needs emergency medical 
attention.  
 
 
 
 
Erythrodermic  
psoriasis  
 
This is a rare and severe type of psoriasis. Most or all of the 
skin on your body becomes red and inflamed. It needs 
emergency medical attention.  
 
 
 
Scalp, nail, 
facial and 
flexural 
psoriasis 
 
Psoriasis can be more difficult to treat on some parts of the 
body. Flexural psoriasis happens in skin folds, armpits, under 
the breast, between buttocks and in the groin area where it 
can affect the genitals.  
 
 
 
1. AVAILABLE FORM OF ANTIPSORIATIC DRUGS 
AND POTENTIAL LIMITATION IN THE 
TREATMENT OF PSORIASIS. 42 
In this section, we review a few conventional and wide 
available treatments of psoriasis from topical, systemic and 
photo or radiation therapies. 
1.1. Topical therapy 
Topical therapy is the main psoriasis treatment with more 
than50% of patients using it as compared to the other 
therapy.16Antipsoriatic drugs for dermal use are 
commercially available generally in the form of gels, 
shampoos, creams, ointments or lotions. In plaque psoriasis 
cases ,the most prescribed topical medication is from the 
corticosteroid family such as hydrocortisone, 
betamethasone, dexamethasone, etc. Even though many 
methods have been offered to deliver corticosteroids, a 
major problem of using this range of drugs is their side 
effects, which include cutaneous atrophy, development of 
striae, formation of telangiectasia and perioral dermatitis on 
the face.17 Moreover, although using topical corticosteroid is 
highly effective initially, it leads to the development of 
tachyphylaxis problem which is a rapidly diminishing 
response to successive doses of a drug, rendering it less 
effective with prolonged use.18 Besides, this type of steroidal 
drug would cause decolourisation and thinning of the skin 
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followed by easy bruising even with a minimum shear.19 
Thus, it is not suitable for face and also for children. 
1.2. Systemic therapy 
Systemic therapy includes methotrexate, cyclosporine and 
antibody therapy. Methotrexate is the oldest therapy and one 
of the most effective treatments. However, it gives a short 
term side effect of bone marrow toxicity which could lead to 
death.20 Another side effect includes nausea, aphthous 
stomatitis and development of megaloblastic anaemia.18 
Besides, the use of methotrexate should be prescribed with 
caution in the presence other patient's conditions including 
obesity, diabetes and heavy alcohol intake because of the 
increase risk of liver fbrosis.21 
1.3. Phototherapy 
Photo or light therapy also includes radiation therapy using 
usually ultraviolet source.22 The combination of ultraviolet B 
(UVB) with topical treatment such as tar or emollient is still 
been used in current medication of psoriasis. Broadband 
UVB is reported to be one of the safest treatments for 
psoriasis. However, it needs to be done at least three times 
per week for several months to see the result.22 Narrowband 
UVB is more effective than the broadband UVB 
phototherapy.23 PUVA is another treatment of phototherapy 
which involves the use of psoralen and ultraviolet A. A light-
sensitive drug, psoralen absorbs long wavelength ultraviolet 
(UVA) light. Psoralens are either taken orally or applied 
topically where the infected area of patient's skin will be 
immersed in water containing 8-methoxypsoralen capsules, 
which is followed exposing this area with the UVA light.24,25 
Despite its effectiveness to clear the symptoms the affected 
area, it is associated with the development of skin squamous 
cell carcinomas leading to the development of a skin cancer 
in the thin, at squamous cells.18 Even though PUVA and UVB 
seem to be effective towards psoriasis disease, but the 
impracticality of its application has been the main issue for 
many patients.26 
2. CHALLENGES IN TOPICAL TREATMENT OF 
PSORIASIS42 
Stratum corneum is the main barrier in the percutaneous 
absorption of topically applied drugs. The successful 
performance of these systems for drug delivery completely 
depends on their capability to penetrate through several 
barriers of the skin, drug release and their stability in the 
nanoscale size. However, for the topical treatment of 
psoriasis using drug delivery system, there still remain two 
major challenges. Firstly, the lack of efficient carrier for 
delivery of anti-psoriatic drugs where efficient delivery of 
antipsoriatic drug depends on variety of physicochemical 
characteristics of the carrier and the active moiety used,14 
leading to variation in drug absorption and the drug efficacy. 
Secondly, appropriate animal model with completely 
psoriatic condition is lacking for in vitro and in vivo studies. 
(1) Psoriatic lesions can have both significantly thickened 
and thinned epidermis. Different morphology of the 
skin could increase the diversity in drug absorption, 
hence increase challenges in formulation development 
(2)  Most patients with psoriasis feel that the current 
therapy is either not effective or not aggressive enough. 
Therefore, to develop a new therapy which can be once 
a day 
Application and shows quick response is another 
challenge. 
(3) Effective management of psoriasis o en requires 
combining therapy to achieve optimal response while 
minimizing side effects. Therefore, any new topical 
therapy should have the appropriate safety and efficacy 
when used in combination with another topical 
medication, for example systemic therapy and/ or 
phototherapy. 
(4)  New topical formulations must have appropriate 
cosmetic elegance such as ease of use, no potential 
staining on clothing, bedding, etc., upon the application 
of rapid absorption and less greasy in order to improve 
patient's adherence to therapy. 
(5) The formulations which can be used in many areas of 
the body including the hair-bearing sites are preferred 
by patients with plaque psoriasis. 
(6)  For the various types of therapy and the presence of 
generic products on the market, the competitive costs 
of any new drugs is the most important in influuencing 
the choices of the product.13,15 
3. NANOEMULSIONS: NOVEL COLLOIDAL DRUG 
DELIVERY SYSTEM FOR PSORIASIS42 
An emulsion is a dispersed system containing at least two 
immiscible liquid phases. In order to ensure stability, an 
emulsion must contain a suitable emulsifying agent aside 
from the dispersed phase and dispersion medium1, 2. There 
are two basic forms of emulsion. The first is the oil-in 
water(O/W) emulsion in which oil droplet are dispersed and 
encapsulated within the watercolumn3.The second is the 
water-in-oil (W/O) emulsion in which droplet of water is 
dispersed and encapsulated within the oil. An o/w emulsion 
is formed when a small amount of an appropriate surfactant 
is mechanically agitated with the oil in water. this results in a 
two phase dispersion where one phase exists as droplets 
coated by surfactant that is dispersed throughout the 
continuous, other phase.4 These emulsion are milky or turbid 
in appearance due to the fact that the droplet size range from 
0.1 to 1 micron in diameter. As a general rule, the types of 
surfactant used in the system determine which phase is 
continuous. If the surfactant is hydrophilic, then oil will be 
emulsified in droplets throughout a continuous water phase. 
The opposite is true for more lipophilic surfactants. In w/o 
water phase emulsified in droplets that are dispersed 
throughout a continuous oil phase in this case5.6 
Nanoemulsions  are transparent (translucent) dispersions of 
oil and water stabilized by an interfacial film of surfactant 
and co-surfactant molecules having a droplet size of less than 
1000 nm. Nanoemulsion, is a multiphase colloidal dispersion, 
is generally identified by its stability and clarity. Apply high 
shear generally obtained by micro fluid or ultrasonic 
approach generally used to reduce the droplet size to 
nanoscale. Various works are done to correlate the different 
transdermal drug release from various delivery systems. 4 
4. NANOEMULSION IN TOPICAL APPLICATION43 
Nanoemulsion is a novel drug delivery system alternative to 
increase drug delivery and increasing efficacy of poorly 
soluble drugs, by increasing its absorption through the skin, 
better retention time of drug in the target area and prevent 
the side effects 31. The benefits of nanoemulsion with 
globules in nano-scale size of an emulsion does not relay on 
the emulsion physical properties itself 32, yet encounter the 
bioavailability of therapeutic drugs in whole. Apparently, 
there have been researches on the bioavailability of 
lacidipine via transdermal route was 3.5 times higher than 
that of oral route which believed to be due to avoidance of 
first-pass metabolism 33.  In nanoemulsion, the small size of 
particles, the more quantity of drug is able to be 
incorporated in nano globules, which subsequently increases 
Nimase et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):659-664 
ISSN: 2250-1177                                                                                  [662]                                                                                 CODEN (USA): JDDTAO 
the thermodynamics towards the skin.  One of the studies 
consequently narrates the implications of Nile red (NR) dye 
loaded in lecithin nanoemulsion was able to penetrate the 
skin 9.9-fold greater than the NR-loaded general emulsion 34. 
Besides that, ethyl oleate and propylene glycol, ingredients 
used and it act as permeation enhancers 35.  
The greatest difficulty upon transdermal drug delivery refers 
to barrier properties of stratum corneum a 10 μm to 20 μm 
thick tissue layers with great composed structured 
lipid/protein matrix 36. On recent study, of demal delivery 
lipophilic flurbiprofen in nanoemulsion proves and an 
increase in efficacy by 4.4 times compared to oral 
administration 37. Hence, the nanoemulsion is a spontaneous 
easy emulsifying method which provides more advantages 
over other carrier such as polymeric nanoparticle and 
liposomes, including low cost preparation procedure, high 
hydrophilic and lipophilic drug loading system to enhance 
the longer shelf live upon preserving the therapeutic agents 
37. 
5. ADVANTAGES AND DISADVANTAGES 44, 38 
5.1.   Advantages 
a) Increase the rate absorption. 
b) Eliminates variability in absorption. 
c) Helps solubilize lipophilic drug. 
d) Provides aqueous dosage form for water insoluble 
drugs. 
e) Increases bioavailability. 
f) Various routes like topical, oral and intravenous can be 
used to deliver the product. 
g) Rapid and efficient penetration of the drug moiety. 
h) Helpful in taste masking. 
i) Provides protection from hydrolysis and oxidation as 
drug in oil phase in O/W Nanoemulsion is not exposed 
to attack by water and air. 
j) Liquid dosage form increases patient compliance. 
k) Less amount of energy requirement. 
l) Nanoemulsions are thermodynamically stable system 
and the stability allows selfemulsion of the system. 
5.2.  Disadvantages 
a) Use of a large concentration of surfactant and co-
surfactant necessary for stabilizing the nanodroplets. 
b) Limited solubilizing capacity for high-melting 
substances. 
c) The surfactant must be nontoxic for using 
pharmaceutical applications. 
d) Nanoemulsion stability is influenced by environmental 
parameters such as temperature pH. 7.  
6. COMPONENTS IN THE TOPICAL NANOEMULSION 
FORMULATIONS FOR ANTIPSORIATIC DRUGS 45 
6.1 Oil Phase  
Selection of oil phase such as saturated and unsaturated fatty 
acids/fatty acid esters like castor oil, coconut oil, corn oil, 
cottonseed oil, evening primrose oil, fish oil, jojoba oil, lard 
oil, linseed oil, mineral oil, olive oil, peanut oil, PEG-vegetable 
oil, perfluro chemicals, pine nut oil, safflower oil, sesame oil, 
soybean oil, squalene, sunflower oil, wheat germ oil can be 
done. Oil phase helps in penetration of drugs. Mostly 
antipsoriatic drugs are lipophilic and have a log P value of 3, 
which makes it suitable for being encapsulated in emulsion. 
Sometimes combination of oils is used to encapsulate 
antipsoriatic drugs 40.  
6.2 Surfactant  
Selection of surfactant is used to decrease the interfacial 
tension and makes a stable emulsions having requisite 
particle size, but which also ensure minimal skin irritancy 
there are basically four types of surfactants i.e. nonionic, 
zwitterionic cationic, anionic.. Commonly used surfactants 
include Tween®, Cremophor®, Transcutol® P, Plurol 
Oleique®, Plurol Isostearique® and Labrasol® , Lecithin, 
Organogels 41.  
6.3 Co-surfactant  
Cosurfactants are generally used to modify the curvature and 
fluidity of the interfacial film, leading to the decrease of 
interfacial tension. Cosurfactants are short and medium 
chain alcohols and polyglyceryl derivatives, including 
ethanol, isopropanol, isopropyl myristate and propylene 
glycol (PG) 40.  
6.4 Other Excipients  
Antioxidants (a-tocopherol, ascorbic acid) Tonicity modifiers 
(glycerol, sorbitol, xylitol) pH adjustment agents (NaOH or 
HCl) Preservatives, aqueous phase (sodium chloride and 
buffer salts) and penetration enhancers, Viscosity enhancing 
agents (e.g., Carbopol®, Aerosil®, gelatin) are incorporated 
to reduce the fluidity and generate the desired final 
consistency of the product 39. 
7. METHODS OF PREPARATION OF NANOEMULSION 
45 
There are basically two methods of preparation of 
nanoemulsion as shown in figure 3. High energy 
emulsification methods generate highly disrupting forces 
that break down the oil and water phases, causing them to 
intersperse and form nanometer-sized droplets. Whereas 
low energy emulsification methods include heat, stirring and 
phase inversion.  
7.1 High Pressure Homogenization  
This is highly efficient method of preparation of 
nanoemulsion in which forcefully introduction of oil and 
water along with surfactants, cosurfactants are passed 
through a small orifice at high pressure. At first, emulsion is 
formed with large volume fraction of dispersed phase, which 
may be diluted later on. Excess amount of surfactants are 
added to avoid coalescence40.  
7.2 Microfluidisation  
In this method water and oil are introduced through small 
orifice by pressure pump from opposite direction into mixing 
area, where they mixed with other high shear and converted 
into small droplets which in turn used to prepared 
nanoemulsion.  
7.3 Sonication  
It is widely used method in which probe sonicator is placed 
in the mixture oil and water with surfactants, cosurfactants 
to give mechanical force by which dispersion is converted 
into small sized droplets. 
7.4 Phase inversion temperature technique41, 42 
In this technique at room temperature oil, water and 
surfactants are mixed and then temperature is increased, 
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then surfactant mixed in the oily phase. Due to change in 
temperature phase inversion prevents coalescence and 
produce stable nanoemulsions.  
7.5 Solvent displacement method  
In this method nanoemulsions can be prepared by pouring 
the organic phase containing oil dissolved in a solvent into 
aqueous phase having surfactants at room temperature. The 
preparation of nanoemulsion occurs by diffusion of organic 
solvent, evaporated by vacuum. Small sized droplets of 
nanoemulsion can be prepared by taking appropriate ratio of 
solvent to oil. 40 
7.6 Spontaneous emulsification  
In the solution of oil and surfactant water is added at 
constant temperature and mixed lightly to produce o/w 
nanoemulsions. The preparation of nanoemulsion depends 
on surfactant structure, its concentration, interfacial tension, 
interfacial and bulk viscosity, phase transition region 39,41. 
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